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Summary
Background Silicone adhesive multilayer foam dressings are used as adjuvant ther-
apy to prevent hospital-acquired pressure ulcers (PUs).
Objectives To determine whether silicone foam dressings in addition to standard
prevention reduce the incidence of PUs of category 2 or worse compared with
standard prevention alone.
Methods This was a multicentre, randomized controlled medical device trial con-
ducted in eight Belgian hospitals. At-risk adult patients were centrally randomized
(n = 1633) to study groups based on a 1 : 1 : 1 allocation: experimental groups
1 (n = 542) and 2 (n = 545) – pooled as the treatment group – and the control
group (n = 546). The experimental groups received PU prevention according to
hospital protocol, and a silicone foam dressing on the relevant body sites. The
control group received standard of care. The primary endpoint was the incidence
of a new PU of category 2 or worse at the studied body sites.
Results In the intention-to-treat population (n = 1605), PUs of category 2 or
worse occurred in 40% of patients in the treatment group and 63% in the con-
trol group [relative risk (RR) 064, 95% confidence interval (CI) 041–099,
P = 004]. Sacral PUs were observed in 28% and 48% of the patients in the
treatment group and the control group, respectively (RR 059, 95% CI 035–
098, P = 004). Heel PUs occurred in 14% and 19% of patients in the treat-
ment and control groups, respectively (RR 076, 95% CI 034–168, P = 049).
Conclusions Silicone foam dressings reduce the incidence of PUs of category 2 or
worse in hospitalized at-risk patients when used in addition to standard of care.
The results show a decrease for the sacrum, but no statistical difference for the
heel and trochanter areas.
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What is already known about this topic?
• The incidence of hospital-acquired pressure ulcers (PUs) remains high despite the
implementation of best-practice recommendations.
• The concept of using silicone foam dressings as an additional prophylactic strategy
in PU prevention has been investigated in previous studies but with some limita-
tions.
• Most RCTs were monocentric studies, restricted to either critically ill or acute care
patients and did not observe more than two anatomical at-risk skin sites, which
limited the generalizability of the findings.
What does this study add?
• This large pragmatic RCT suggests that it is beneficial to use silicone adhesive mul-
tilayer foam dressings on the sacrum, in addition to standard of care, to help pre-
vent hospital-acquired PUs.
• Clinical decision making for heel dressings should be based on the clinical effec-
tiveness of the intervention weighed against the potential risk of falling.
Pressure ulcers (PUs) or pressure injuries are localized injuries
to the skin and/or underlying tissue, usually over a bony
prominence, as a result of pressure, or pressure in combina-
tion with shear.1 The burden of hospital-acquired PUs (HA-
PUs) is high on patients and healthcare systems.2 A systematic
review presented the pooled prevalence of HA-PUs among
1 366 848 patients as 128%, a pooled incidence rate of 54
per 10 000 patient-days (n = 681 885), and the pooled rate
of HA-PUs among 1 893 593 patients as 84%.3 Two large
studies determined that most category 2–4 PUs occur in the
sacral area (450–517%) and the heels (267–407%), fol-
lowed by the greater trochanter area (18–26%).4,5 Interna-
tional guidelines recommend to reduce both the amount and
the duration of pressure and shear, by implementing strategies
that include regular and comprehensive risk assessment,
patient repositioning, skincare, incontinence management,
nutritional care, and the use of pressure redistribution sur-
faces.1,6
There is growing international interest in the application of
dressings covering areas at risk for PUs, to reduce the mechan-
ical impact on the skin and underlying tissue. The clinical
effectiveness has been summarized in five systematic reviews7–11
– covering six randomized controlled trials (RCTs)12–17 with a
total of 1985 recruited patients – and an additional RCT pub-
lished recently.18 The RCTs were mostly monocentric studies
and/or restricted to critically ill patients, and observed only
one or two body sites (sacrum and/or heels).12–18 These stud-
ies were either funded by industry13,15,17,18 or funders were
not reported.12,14,16
Silicone foam dressings, depending on their construction,
redistribute pressure over larger areas, mitigate external shear-
ing forces on the skin (multiple layers), and might assist with
maintaining the microclimate for the skin to function
normally (foam structure or layers and film breathabil-
ity).7,8,16,19 Silicone-based adhesives are incorporated into the
dressings, which compared with traditional adhesives attach
faster to uneven skin surfaces, are gentle to remove, and can
be repositioned.20,21 This allows skin visualization without
replacing the dressing after lifting.
The aim of this study was to determine whether silicone
adhesive multilayer foam dressings used in combination with
standard of care would reduce the incidence of PUs of cate-
gory 2, 3 or 4; unstageable PUs; and deep tissue injuries (re-
ferred to as PU category 2 or worse) on the sacrum, heels and
greater trochanters of adult hospitalized patients in intensive
care units (ICUs) and non-ICU wards.
Patients and methods
Study design
This was a pragmatic, multicentre, randomized (1 : 1 : 1 allo-
cation), open-label, parallel-group medical device trial per-
formed in eight hospitals (three university or teaching
hospitals and five general hospitals) in Belgium, including
patients on both ICU and non-ICU wards, with patients in
ICU limited to < 25%.
Participants
The sample-size calculation was based on the results of several
randomized trials with an incidence of 6% of PU category 2
or worse on the sacrum, greater trochanter and heels in the
standard of care (SOC) group,4 and the treatment group hav-
ing a 50% reduction in incidence of PUs of category 2 or
worse.2,22 To have 80% power to detect a reduction in PU
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incidence from 6% to 3%, data had to be available for 1578
patients in total, of whom 526 had to be allocated to the con-
trol group and 1052 to the treatment group. Considering a
5% dropout rate, a total of 1662 patients had to be random-
ized to ensure enough patients would complete the trial with-
out compromising the statistical power. The study was not
powered to analyse subgroups.
Patients aged > 18 years who gave written informed con-
sent (patient or proxy) were included if they were: (i) at risk
for PU development based on Braden risk assessment23 (Bra-
den score < 17); (ii) had been admitted to the hospital within
the previous 48 h; (iii) had no PU of category 2 or worse
present on the sacrum; and (iv) had no clinically relevant
incontinence-associated dermatitis or other skin condition that
would be a contraindication for application of the study
devices. The Braden scale was applied in all participating sites
and in all units (both ICU and non-ICU) because the scale is
used nationally to assess risk for PU development (even in the
ICU). The study team decided not to change the SOC. Patients
could still be included if, at three of the other four sites (heel
left/right and trochanter left/right), prevention could be
applied or a PU category 2 or worse already existed. Full
inclusion and exclusion criteria are available in the clinical
study protocol (Appendix S1; see Supporting Information).
Randomization and blinding
Patients were centrally randomized to study groups based on a
1 : 1 : 1 allocation: experimental group 1 (Allevyn brand),
experimental group 2 (Mepilex brand) and the control group
(SOC). Experimental groups 1 and 2 were pooled in the anal-
ysis as the treatment group. Randomization was stratified by
hospital and ICU vs. non-ICU wards. The randomization was
based on a permuted-block randomization with varying block
sizes. For each group of wards (ICU vs. non-ICU) the ran-
domization schedule ensured balance of the three study
groups at the intended number of randomized patients.
Patients, caregivers and study personnel were not blinded to
the study procedures as blinding is not possible when using
different types of dressings.
Intervention
The study interventions are summarized in Figure 1. Standard
hospital protocols for prevention of PUs were used in the SOC
and treatment groups, with addition of the silicone foam
dressings as the only variable in the treatment group.
Dressings were commercially available, purchased by the
sponsor and delivered to the hospitals by the manufacturers.
The university-based study team did extensive training with
the study sites regarding the PU prevention and study proto-
cols, correct indication, and application of the study devices.
In total 1192 nurses across 74 wards were trained during 124
sessions. Dressings were maintained on the treatable skin sites
and were changed according to the manufacturer’s instructions
for use. The study nurse inspected the skin beneath the
dressing daily, by lifting the dressing and reapplying (not
replacing) it.
If the patient developed a PU of category 2 or worse, or
developed incontinence-associated dermatitis, the application
of the study device was stopped, and treatment of the PU was
started according to the hospital’s wound care protocol. Pho-
tographs were taken whenever a PU of category 2 or worse
developed and were transferred to the chief investigator for
blinded central review.
Outcomes
The primary endpoint of this trial was the proportion of
patients who developed at least one new PU of category 2 or
worse on the sacrum, heels or greater trochanter as judged on
site, during the trial period of the patient (maximum
14 days). These proportions were compared between the
pooled treatment group and the SOC group as per the ran-
domization scheme. An intention-to-treat (ITT) analysis
including all patients randomized, and a per protocol (PP)
analysis was performed. Exploratory analyses (ITT and PP)
compared new PU incidence between the anatomical sites
(sacrum, trochanters and heels) and the experimental investi-
gational devices (experimental groups 1 and 2). Subgroup
analyses of the primary endpoint were performed on patient
characteristics: age, sex, type of ward, surgery, body mass
index (BMI), diabetes and Braden score.
Statistical analysis
The primary analysis of the primary efficacy variable consisted
of a superiority analysis that compared the incidence in the
pooled treatment group vs. the control group, by means of
the Cochran–Mantel–Haenszel (CMH) test controlled for type
of ward (ICU or non-ICU) on the ITT population. Superiority
was concluded if the estimated impact of the treatment vs.
control group was significant, based on a two-sided test at 5%
significance level. Patients with missing data were defined as
those without any assessment of the primary endpoint after
randomization. These patients were excluded from the ITT
population.
For exploratory analysis, the primary endpoint was com-
pared firstly between the treatment group and the control
group and secondly between experimental group 1 and exper-
imental group 2 (experimental investigational devices) by
means of the CMH test, and controlled for type of ward (ICU
or non-ICU) in the ITT and PP populations (Appendix S2; see
Supporting Information). Logistic regression models were
used, adjusted for hospital, age, sex, type of ward and Braden
score category (in the ITT and PP populations).
A sensitivity analysis of the primary endpoint of confirmed
PU by blinded central review of photographs was conducted
in the ITT population. All efficacy (primary and exploratory)
analyses were reproduced in the PP population.
Descriptive safety analyses were performed, based on
reported adverse device effects (ADEs). An ADE was defined as
© 2020 The Authors. British Journal of Dermatology
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any adverse event related to the device used in the trial.
Device deficiencies (DDs) were defined as the inadequacy of
the study device related to its identity, quality, durability, reli-
ability, safety or performance.
The safety population (n = 1077) was calculated after
exclusion of patients in the ITT population who wanted their
data excluded (n = 1), were not randomized (n = 46), did
not receive at least one dressing (n = 10) or received only
SOC (n = 546).
Statistical analyses were performed using the SAS statistical
package, version 94 (IBM, Armonk, NY, USA).
Ethics
Approval was received from both central (Ghent University
Hospital) and local ethics committees for the trial protocol,
informed consent forms and other relevant documents. The
study was registered at ClinicalTrials.gov (NCT03442777).
Results
Between February and December 2018, 1633 patients were
centrally randomized to one of the study groups: 542
(332%) to experimental group 1, 545 (334%) to experimen-
tal group 2 and 546 (334%) to the SOC group.
Of the 1680 patients screened for eligibility, 46 patients
were not randomized and one patient requested to have their
data excluded from the analyses. Figure 2 summarizes the par-
ticipant flow.
Among the 1633 randomized patients, approximately
610% were > 80 years old (mean age 796 years, SD 122,
range 283–1037), and the majority were female (576%)
and from non-ICU wards (875%). Patients who were under-
weight (BMI < 185 kg m2) accounted for 83% of the
sample (n = 136), 297% were overweight (BMI 250–
300 kg m2) and 165% had obesity (BMI > 30 kg m2).
The patient characteristics were equally distributed across the
three groups. The baseline demographics are displayed in
Table 1.
Of the 1605 patients in the ITT population, 77 (48%)
developed a PU of category 2 or worse: 40% in the treatment
group and 63% in the SOC control group. The CMH test,
controlled for type of ward (ICU or non-ICU), showed a sta-
tistically significant reduction of the risk to develop a PU in
the treatment group [relative risk (RR) 064, 95% confidence
interval (CI) 041–099, P = 004], meaning that patients in
the treatment group had a 36% risk reduction of developing a
new PU compared with those in the SOC group (Table 2).
This result was confirmed when using a logistic regression
model, adjusted for hospital, age, sex, type of ward (ICU or
non-ICU) and Braden score at baseline (P = 001). The num-
ber needed to treat to prevent one new PU of category 2 or
worse from developing was 43.
With exploratory analyses, new PUs on the sacrum were
observed in 28% and 48% of patients in the treatment and
SOC groups, respectively. The risk of developing a new PU on
the sacrum was statistically significantly reduced by 41% in
the treatment group (RR 059, 95% CI 035–098, P = 004).
The number needed to treat to prevent one new PU of cate-
gory 2 or worse on the sacrum was 50. PUs on the heels
occurred in 14% and 19% of patients in the treatment and
SOC groups, respectively, and no statistical difference was
identified (RR 076, 95% CI 034–168, P = 049). Only one
patient (01%), in experimental group 1, developed a PU on
the trochanter (Table 2). Exploratory data analyses did not
demonstrate any major differences in effectiveness between
the two brands, considering that the study was not powered
to detect such differences.
Figure 1 Interventions and procedures. IAD, incontinence-associated dermatitis; PU, pressure ulcer.
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The incidence of PUs increased with age (from 08%
for < 60 years to 59% for ≥ 80 years) and was higher
among women then among men (51% vs. 44%). The inci-
dence of PUs decreased across Braden score categories
(Table 3), from 67% (Braden score ≤ 11) to 43% (Braden
score 12–16) and 16% (Braden score ≥ 17). In the high-risk
group (score ≤ 11), the incidence was higher in the experi-
mental group (79%) than in the SOC group (40%), while it
was the inverse in the mild risk category (28% in the experi-
mental group vs. 73% in the SOC group).
A sensitivity analysis was conducted (ITT population) based
on centrally confirmed PUs by blinded review of photographs
by the chief investigator. Among the 77 new PUs of category
2 or worse reported by local assessment in the ITT population
(n = 1065), 68 had photographs of sufficient quality and
were assessed. Of these, 56 (82%) were confirmed as a PU of
category 2 or worse by central review. All PP analyses con-
firmed the ITT analyses, as described in the clinical study
report.24
No serious ADEs were reported in the safety population
(n = 1077) during the study. Thirty-three ADEs were reported
in 28 patients. Most of them were mechanical skin injuries
(skin tears or skin stripping, n = 11), PU formation (two of
PU category 1, one of PU category 2) and blister formation at
the edge of or underneath the dressing (n = 3). These injuries
were anecdotally attributed to the dressing being ‘rolled up’,
having ‘rolled edges’ or being ‘wrinkled up’, alluding to the






- Asked to have data excluded from the 
analysis, n = 1 (2.1%)
- Not randomized (n=46, 74.5%)
Allocated to Allevyn® Life 
n=542 (33.2%)
- Received Mepilex® Border, n=0 
(0.0%) 
- Received no dressings, n=0 
(0.0%)
Allocated to Mepilex® Border
n=545 (33.4%)
- Received Allevyn® Life 
once, besides 13 Mepilex®
Border on sacrum, n=1 (0.2%)
- Received no dressings, n=0 
(0.0%)
Allocated to Standard of Care
n=546 (33.4%)




- Assessed only once and no 




- Assessed only once and no 




- Assessed only once and no 
pressure ulcer or category I at any 
site, n=7
Analyses
Reasons for end of study
n=397 (73.2%)
- No at risk of pressure ulcers 
anymore (n=115, 21.2%)
- Withdrew (n=32, 5.9%) 
- Discharged from hospital 
(n=184, 33.9%)
- Moved to non-participating 
ward (n=20, 3.6%)
- Death (n=27, 4.9%)
- Other (n=19, 3.5%)
Discontinuation of intervention
n=35 (6.5%)
- Noncompliance (n=2, 0.4%)
- Worsening medical condition 
(n=14, 2.6%), 
- Patients best interest (n=4, 
0.7%)
- Contraindications (n=1, 0.2%)
- Other (n=14, 2.6%)
Reasons for end of study
n=386 (70.8%)
- No at risk of pressure ulcers 
anymore (n=101, 18.5%)
- Withdrew (n=22, 4.0%) 
- Discharged from hospital 
(n=188, 34.4%)
- Moved to non-participating 
ward (n=28, 5.1%) 
- Death (n=23, 4.2%)
- Other (n=24, 4.4%)
Discontinuation of intervention
n=41 (7.5%)
- Noncompliance (n=1, 0.2%)
- Worsening medical condition 
(n=16, 2.9%), 
- Patients best interest (n=4, 
0.7%)
- Contraindications (n=2, 0.3%)
- Other (n=18, 3.3%)
Reasons for end of study
n=371 (67.9%)
- No at risk of pressure ulcers 
anymore (n=114, 20.8%)
- Withdrew (n=3, 0.5%) 
- Discharged from hospital 
(n=182, 33.3%)
- Moved to non-participating 
ward (n=29, 5.3%) 
- Death (n=24, 4.3%)
- Other (n=19, 3.4%)
Patient disposition
Figure 2 Participant flowchart. PU, pressure ulcer.
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tension injuries on the skin. Heel dressings caused two patient
falls, without significant harm, when the dressing was in
direct contact with the floor (Table 4).
From the DD group in the safety population, 246 DDs
were reported in 97 patients. Some of the seven categories
identified related to the subsequent ADEs reported, namely
poor adhesion or adhesion failure (n = 127), rolled-up
edges (n = 44) and dressing causing the floor to be slippery
for others (n = 26); in one case of the latter this resulted
in a fall, without significant harm. Other DDs noted were
dressing layer separation, adhesive residue on the skin,
adhesive transfer or poor release of the backing film or liner
from the dressing, and footwear obstruction (Table 4).
Discussion
The use of silicone adhesive multilayer foam dressings for PU
prevention at the sacrum, heels and trochanters significantly
decreased the incidence of PUs of category 2 or worse from
63% to 40% in hospitalized at-risk patients.
Table 1 Participants’ baseline data (frequencies and descriptive) and total Braden scores at baseline: by randomized arm, intention-to-treat
population
Randomized arm Allevyn Life (n = 542) Mepilex Border (n = 545) Standard of care (n = 546) Total (n = 1633)
Ward type at start of study
ICU 65 (12) 67 (12) 71 (13) 203 (12)
Non-ICU 477 (88) 478 (88) 475 (87) 1430 (88)
Age (years)
< 60 46 (8) 43 (8) 45 (8) 134 (8)
60–69 50 (9) 70 (13) 56 (10) 176 (11)
70–79 106 (20) 107 (20) 117 (22) 330 (20)
≥ 80 340 (63) 325 (59) 328 (60) 993 (61)
Median (IQR) 831 (747–882) 831 (726–883) 827 (734–875) 830 (737–879)
Sex
Female 320 (59) 302 (55) 319 (58) 941 (58)
Male 222 (41) 243 (45) 227 (42) 692 (42)
BMI (kg m2)
Underweight (< 185) 44 (8) 53 (10) 39 (7) 136 (8)
Normal weight (185–250) 234 (43) 249 (45) 258 (47) 741 (45)
Overweight (250–300) 161 (30) 163 (30) 162 (30) 486 (30)
Obesity (≥ 300) 103 (19) 80 (15) 87 (16) 270 (17)
Median (IQR) 248 (218–284) 242 (213–276) 245 (217–279) 245 (215–280)
Diabetes
No 419 (77) 427 (78) 412 (75) 1258 (77)
Yes 123 (23) 118 (22) 134 (25) 375 (23)
Total Braden score
≤ 11 129 (24) 142 (26) 126 (23) 397 (24)
12–16 392 (72) 376 (69) 403 (74) 1171 (72)
17 21 (4) 27 (5) 17 (3) 65 (4)
Median (IQR) at baseline 13 (120–150) 14 (110–150) 13 (120–150) 13 (120–150)
The data are presented as n (%) unless indicated otherwise. BMI, body mass index; ICU, intensive care unit; IQR, interquartile range.
Table 2 Estimated relative risks (RRs) and 95% confidence intervals (CIs) for pressure ulcers of category 2 or worse, in the experimental group
compared with the standard-of-care group (intention-to-treat analyses)
Experimental, n/N (%) Standard of care, n/N (%) RRa (95% CI) P-value
Overall 43/1066 (40) 34/539 (63) 064 (041–099) 004
Body site
Sacrum 30/1062 (28) 26/539 (48) 059 (035–098) 004
Any heel 15/1063 (14) 10/538 (19) 076 (034–168) 049
Any trochanter 1/1065 (01) 0/539 (0) n/a n/a
aRR with reference to the standard-of-care group. n/a, not applicable.
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Exploratory analyses (per anatomical site and between
experimental groups) were performed to investigate specific
interactions on the primary outcome. Any apparent lack of
effect should be regarded with caution as the trial was not
specifically powered with interactions in mind. The results
show a decrease in PUs of category 2 or worse for the sacrum
Table 3 Incidence of pressure ulcers of category 2 or worse, by intervention group stratified by patient characteristics (intention-to-treat analyses)
Treatment, n = 1066 Standard of care, n = 539) Total, n = 1605
Pressure ulcer
All Yes 43 (40) 34 (63) 77 (48)
No 1023 (960) 505 (937) 1528 (952)
Age (years)
< 60 Yes 0 (0) 1 (2) 1 (08)
No 81 (100) 44 (98) 125 (992)
60–69 Yes 2 (17) 2 (4) 4 (23)
No 116 (983) 53 (96) 169 (977)
70–79 Yes 8 (38) 6 (52) 14 (43)
No 205 (962) 109 (948) 314 (957)
≥ 80 Yes 33 (50) 25 (77) 58 (59)
No 621 (950) 299 (923) 920 (941)
Sex
Female Yes 27 (44) 20 (63) 47 (51)
No 581 (956) 296 (937) 877 (949)
Male Yes 16 (35) 14 (63) 30 (44)
No 442 (965) 209 (937) 651 (956)
Baseline ward
ICU Yes 6 (48) 3 (4) 9 (46)
No 118 (952) 68 (96) 186 (954)
Non-ICU Yes 37 (39) 31 (66) 68 (48)
No 905 (961) 437 (934) 1342 (952)
Surgery
No Yes 39 (41) 30 (62) 69 (48)
No 913 (959) 454 (938) 1367 (952)
Yes Yes 4 (35) 4 (7) 8 (47)
No 110 (965) 51 (93) 161 (953)
BRADEN at baseline
≤ 11 Yes 21 (79) 5 (40) 26 (67)
No 244 (921) 119 (960) 363 (933)
12–16 Yes 21 (28) 29 (73) 50 (43)
No 734 (972) 369 (927) 1103 (957)
17 Yes 1 (2) 0 (0) 1 (2)
No 45 (98) 17 (100) 62 (98)
BRADEN – Sensory Perception
Completely limited or very limited Yes 18 (76) 7 (58) 25 (70)
No 220 (924) 113 (942) 333 (930)
Slightly limited or no impairment Yes 25 (30) 27 (64) 52 (42)
No 803 (970) 392 (936) 1195 (958)
BRADEN – Activity
Bedfast/chairfast Yes 42 (43) 34 (68) 76 (52)
No 928 (957) 465 (932) 1393 (948)
Walks occasionally or walks frequently Yes 1 (1) 0 (0) 1 (07)
No 95 (99) 40 (100) 135 (993)
BRADEN – Mobility
Completely immobile/very limited Yes 39 (48) 23 (55) 62 (50)
No 778 (952) 397 (945) 1175 (950)
Slightly limited/no limitations Yes 4 (16) 11 (92) 15 (41)
No 245 (984) 108 (908) 353 (959)
BRADEN – Nutrition
Very poor/probably inadequate Yes 34 (46) 20 (54) 54 (48)
No 709 (954) 352 (946) 1061 (952)
Adequate/excellent Yes 9 (28) 14 (84) 23 (47)
No 314 (972) 153 (916) 467 (953)
ICU, intensive care unit.
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(from 48% to 28%), but no statistically significant effect for
the heels (decrease from 19% to 14%). The incidence of PUs
on trochanters was too low to identify any effect. These results
are consistent with those from previous trials using silicone
foam dressings.7–11,18 This study further expands the general-
izability of the results as more than one dressing type was
used, the study was performed in different disciplines, and
multiple anatomical sites were included. There were no statis-
tical differences between experimental groups 1 and 2 (de-
tailed in the clinical study report).24
While no serious adverse events were reported, 33 ADEs in
28 patients, and 246 DDs in 97 patients were reported –
including two incidents of patient falling, due to heel dress-
ings being slippery on the floor. The surface of the dressing is
designed to minimize friction (be slippery) and therefore
advice was provided that the dressings should not be placed
directly on the floor, and that shoes or antislip stockings
should be worn, although three patients reported that their
footwear did not fit over the bulk of the dressing. For both
brands there were also reports that placing feet covered by
heel dressings directly on the floor made the floors slippery
and risked staff or other people slipping. In one case this
resulted in a nonstudy individual falling, without significant
harms. This observation appeared to be made more frequently
when the ambient temperature was above 30 °C.
As the trial results showed no clear effect on the heels, a
risk–benefit analysis should be considered when applying pro-
phylactic dressings on the heels to determine whether any
potential benefits of protecting the heels outweigh the
reported risk of falls. The product specifications highlight dif-
ferences in construction and adhesive properties between the
two study dressings. This may explain the differences in the
ADEs and DDs (Table 4). No known standards exist for this
product class despite their widespread and growing use. This
conclusion feeds the discussion about the need for perfor-
mance standards for prophylactic dressings. In November
2020, the European Pressure Ulcer Advisory Panel and the
National Pressure Injury Advisory Panel announced the estab-
lishment of an international task force to develop such perfor-
mance standards (https://www.epuap.org/prophylactic-dre
ssing). These standards will generate critical information to
guide (i) effective clinical product selection and practice, (ii)
benchmarks for development purposes and (iii) reimburse-
ment policies.
It should be reiterated that the use of silicone adhesive mul-
tilayer foam dressings might be an additional intervention to
obtain adequate PU prevention, and that the current standard
guidelines for PU prevention still remain the cornerstone of
prevention.1 The risk exists that applying a prophylactic dress-
ing on an at-risk patient will create a false sense of security
for the clinician, leading to the remaining ‘standard of care’
of PU prevention being ignored; however, there was no sug-
gestion of this happening in this study. If prophylactic dress-
ings are added to PU prevention strategies, the protocols
should stress the importance of education, daily skin assess-
ment underneath the dressing, and monitoring of the adher-
ence to the protocol.
There were some limitations to this study. Performance and
detection bias may have occurred because patients, caregivers
and study personnel could not be blinded to the study proce-
dures and devices. However, the results were consistent when
based on confirmed PUs by review of photographs, all study
Table 4 Number of adverse device effects and device deficiencies, safety population
Treatment group
Allevyn Life, n = 539 Mepilex Border, n = 538 Total, n = 1077
Adverse device effect (33 in 28 patients)
All 21 (39) 12 (22) 33 (31)
Pressure ulcer development 1 (02) 2 (04) 3 (03)
Erythema 4 (07) 4 (07) 8 (07)
Pruritus 3 (06) 1 (02) 4 (04)
Blister formation 2 (04) 1 (02) 3 (03)
Exacerbates athlete’s foot 0 (0) 1 (02) 1 (01)
Mechanical skin injuries 8 (14) 3 (06) 11 (10)
Patient fall 2 (04) 0 (0) 2 (02)
Pain at sacrum 1 (02) 0 (0) 1 (01)
Device deficiency (246 in 97 patients)
All 168 (312) 78 (145) 246 (229)
Dressing layers separated 20 (37) 6 (11) 26 (24)
Poor adhesion or adhesion failure 75 (139) 52 (97) 127 (118)
Dressing causes floor to be slippery (increased fall risk) 19 (35) 7a (13) 26 (24)
Adhesive residue 10 (18) 0 (0) 10 (09)
Obstructs wearing footwear 1 (02) 2 (04) 3 (04)
Backing film or liner: adhesive transfer or poor release 10 (19) 0 (0) 10 (09)
Rolled-up edges 33 (61) 11 (02) 44 (41)
The data are presented as n (%). aOne of these cases resulted in another person falling, without significant harms.
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nurses were trained, and for most hospitals their wound care
teams were involved when a PU occurred, further strengthen-
ing the correct identification of skin injuries. As the organiza-
tion of care and staff characteristics is setting specific,
generalizability to other hospitals in other regions might be
limited. However, there was a range of hospital types (univer-
sity and general hospitals), the hospital standard prevention
protocols corresponded to the international state-of-the-art
recommendations, and the treatment effect is consistent with
the results of previous RCTs.
Strengths of this noncommercial study are firstly, its large
size and the pragmatic nature of the trial setup and perfor-
mance. Pragmatic studies can measure realistic treatment
effects in daily clinical routines compared with highly stan-
dardized RCTs. Secondly, the effect estimate is based on cate-
gory 2 or worse PUs. As category 1 PUs are not wounds, the
clinical relevance of this outcome is questionable, and the
measurement error of this outcome is high. Thirdly, the qual-
ity of data collection and high-level education provided by the
study team to the sites are a strength.
Future academic research priorities could include evaluating
the cost and benefit of using prophylactic dressing to reduce
HA-PUs, and if prophylactic dressings are included within
SOC for PU prevention, evaluating the adherence level to a
newly implemented PU protocol.
In conclusion, our study confirmed previous reports from
predominantly small single-centre studies that multilayer
dressings reduce the incidence of sacral PUs in addition to
SOC, both in ICUs and in other wards. Given that on average
50 qualifying hospitalized patients would need to be treated
with supplemental dressings in order to prevent one patient
from developing a PU of category 2 or worse on the sacral
area, a health-economic analysis would be informative before
such intervention is routinely implemented in hospitals.
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